The FAKTION study (NCT01992952), a phase 2 trial, revealed that adding capivasertib to fulvestrant compared with placebo plus fulvestrant extended the survival of participants with AI-resistant HR-positive, HER2-negative advanced breast cancer (Jones et al., 2020; Howell et al., 2022). Here, ERBB2 is linked to breast carcinoma.